Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 17, 2014 16:10 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Positive Topline Results From Phase 2a Pharmacokinetic Trial With Lead Compound FX006

- Following intra-articular injection, sustained release of triamcinolone acetonide (TCA) from FX006 maintained therapeutic concentration levels in knee joints of patients through 12 weeks - -...
June 12, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Announces Changes to Board of Directors

- PathoGenetix President & CEO Ann Merrifield Appointed New Board Member - - Flexion CEO Michael Clayman Offers Thanks to Departing Board Members Bradley Bolzon and Elaine Jones...
June 11, 2014 09:13 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at Wells Fargo Securities Research, Economics & Strategy 2014 Healthcare Conference

BURLINGTON, Mass., June 11, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present at the Wells Fargo Securities Research,...
May 27, 2014 08:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the 2014 Jefferies Healthcare Conference

BURLINGTON, Mass., May 27, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 2014...
May 08, 2014 16:01 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Reports First-Quarter 2014 Financial Results

Key Highlights Completed enrollment of FX006 Phase 2a synovial fluid pharmacokinetics clinical trial with topline data expected in Q2 2014 Initiated confirmatory FX006 Phase 2b clinical...
May 01, 2014 08:30 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report First Quarter 2014 Financial Results on May 8, 2014

BURLINGTON, Mass., May 1, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its first quarter 2014 financial...
April 30, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics Initiates a Phase 2b Confirmatory Dose-Ranging Trial With Lead Compound FX006

BURLINGTON, Mass., April 30, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed...
April 02, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Present at the 13th Annual Needham Healthcare Conference

BURLINGTON, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that CEO Michael Clayman, M.D., will present an overview of the company at the 13th Annual...
March 27, 2014 08:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Reports Year-End 2013 Financial Results

– Strong cash position bolstered with additional $75 million from IPO – – Lead drug candidate, FX006, planned to enter into confirmatory Phase 2b trial in osteoarthritis of the...
March 20, 2014 16:00 ET | Source: Flexion Therapeutics, Inc.

Flexion Therapeutics to Report Year-End 2013 Earning Results on March 27, 2014

BURLINGTON, Mass., March 20, 2014 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that it will host a conference call and webcast to report its year-end 2013 financial...